Physician profile
James B Proctor
NPI 1275746992
$6,101.09
in general payments reported to CMS, 2019-2025
30 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,815 · 2020: $976 · 2021: $1,083 · 2022: $903 · 2023: $507 · 2024: $419 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,038.84 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $834.67 | 2019-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $688.29 | 2019-2024 | Xarelto |
| Amgen INC. | $527.92 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $274.67 | 2019-2024 | |
| Novo Nordisk INC | $191.83 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| United Therapeutics Corporation | $154.04 | 2019-2022 | |
| Philips North America LLC | $137.30 | 2019-2021 | |
| Gilead Sciences, INC. | $131.20 | 2019 | |
| Abbott Laboratories | $114.56 | 2021-2022 | |
| Amarin Pharma, INC. | $109.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $107.61 | 2022-2024 | Verquvo, Winrevair |
| Pfizer INC. | $104.27 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.79 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $83.48 | 2019-2024 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $68.34 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.82 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $48.58 | 2022-2023 | Ekosonic |
| Cardiovascular Systems INC. | $47.24 | 2019-2020 | |
| Esperion Therapeutics, INC. | $37.94 | 2021-2022 | |
| Chiesi USA, INC. | $35.26 | 2021-2023 | Kengreal |
| Irhythm Technologies, INC. | $32.07 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic Vascular, INC. | $24.26 | 2019 | |
| Lundbeck LLC | $22.52 | 2019 | |
| Smith+Nephew, INC. | $16.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.18 | 2019 | |
| Bracco Diagnostics INC. | $13.66 | 2022 | |
| Cvrx, INC. | $13.26 | 2023 | Barostim Neo System |
| Portola Pharmaceuticals, LLC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.